Clinical trials
Primary Breast Cancer clinical trials
Below are recruiting primary breast cancer clinical trials, each written for real people, not researchers. We’re tracking 711 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05592938Recruiting
Partial breast re-irradiation for cancer recurrence
This trial tests a shorter course of radiation to only the part of the breast where cancer has come back. It's for women who had radiation years ago and now have a small new or recurrent tumor that can be removed by surgery.
New York, New YorkAges 18–99 - NCT05570253RecruitingPhase 2
SDX-7320 plus eribulin for metastatic triple-negative breast cancer
This Phase 2 study tests whether adding SDX-7320 to eribulin can work better for people with triple-negative metastatic breast cancer. It focuses on patients who have had prior chemotherapy and who also show signs of metabolic imbalance such as higher body weight or higher HbA1c.
Miami, FloridaAges 18 years+ - NCT05573126RecruitingPhase 1/Phase 2
Study of EP0062 for advanced breast cancer with AR+ and ER+
This Phase 1/2 study tests EP0062, a study medicine given alone or with other treatments, in people with advanced or metastatic breast cancer. It’s designed to see how well it works and what side effects it causes when the cancer has specific hormone-receptor markers (AR+ and ER+) and is HER2-negative.
New Haven, ConnecticutAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study of rinatabart sesutecan for advanced solid tumors
This trial tests an investigational drug called rinatabart sesutecan (also known as Rina-S) for people with advanced solid tumors, including ovarian, endometrial, lung, breast, and other cancers. The drug is designed to target and kill cancer cells, and the study aims to see if it is safe and effective.
Phoenix, ArizonaAges 18 years+ - NCT05512364RecruitingPhase 3
Elacestrant for ER-positive, HER2-negative breast cancer with ctDNA relapse
This trial tests whether elacestrant can help stop or delay breast cancer coming back in people whose blood test shows “ctDNA relapse” after early breast cancer treatment. It’s meant for hormone receptor–positive, HER2-negative breast cancer patients who are already taking hormone (endocrine) therapy and have no visible spread on scans.
AnderlechtAges 18 years+ - NCT04563507RecruitingPhase 2
Immunotherapy plus hormone therapy for metastatic ER-positive breast cancer
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
New York, New YorkAges 18–90 - NCT05483491RecruitingPhase 1
TCR cell therapy for select metastatic cancers
This Phase 1 trial tests a personalized immune-cell treatment (TCR-T cells) for certain metastatic cancers. It targets cancers that carry a specific marker and requires patients to have a specific immune-system match, aiming to improve cancer control when standard options were already tried.
New Brunswick, New JerseyAges 18 years+ - NCT05467891RecruitingPhase 2
Ribociclib plus hormone therapy for recurrent breast cancer
This trial tests whether adding ribociclib (a targeted pill) to hormone therapy can control breast cancer that has come back in the breast area or nearby lymph nodes/chest wall. It targets hormone-receptor–positive and HER2-negative tumors to help slow disease after local treatment.
Birmingham, AlabamaAges 18 years+ - NCT05464810RecruitingEarly Phase 1
Letrozole with or without a cholesterol drug for early breast cancer
This early-phase study tests whether adding simvastatin to letrozole can improve outcomes in people with stage I–III breast cancer that grows with hormone signals (hormone receptor positive) and does not have HER2. It looks mainly at whether the approach is safe and useful for this specific breast cancer type.
Atlanta, GeorgiaAges 18 years+ - NCT05422794RecruitingPhase 1
Adding a new drug plus pembrolizumab to standard chemo for TNBC
This trial studies whether adding a new anti-cancer drug (ZEN-3694) and the immunotherapy drug pembrolizumab to standard chemotherapy (nab-paclitaxel) can work better for advanced triple-negative breast cancer. It’s testing safety first (Phase 1) and, for some patients, how well the treatment controls the cancer.
Boston, MassachusettsAges 18 years+ - NCT05455619RecruitingPhase 1/Phase 2
Targeted drugs for PI3K-altered, HR+/HER2- breast cancer
This Phase 1/2 trial tests how well a combination of targeted medicines works for advanced or returning HR+/HER2- breast cancer that has a PI3K pathway change (such as PIK3CA, PTEN, or AKT1). It may help by blocking growth signals in the cancer and is especially for people whose cancer has progressed after hormone therapy and a CDK4/6 inhibitor.
Loma Linda, CaliforniaAges 18 years+ - NCT05414357Recruiting
Sleep and thinking in breast cancer survivors
This study looks at how sleep problems affect memory, thinking, and quality of life in women who have had breast cancer surgery. If you are having trouble sleeping, joining could help you understand these effects better.
CaenAges 45–65 - NCT05377996RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors with tumor tissue testing
This early-stage study tests emiltatug leda-dotin (Emi-Le) in people with advanced or recurring solid cancers. It aims to see how the drug works and how safely it can be given, using tumor tissue testing to help understand who may benefit.
Phoenix, ArizonaAges 18 years+ - NCT05377047RecruitingPhase 3
High-precision radiation for limited breast cancer spread
This trial tests a high-precision radiation therapy (called stereotactic ablative radiotherapy) to treat breast cancer that has spread to a limited number of spots in the body. It aims to control the cancer and improve outcomes, and you can join while on your first-line systemic treatment if the cancer is stable.
CorkAges 18 years+ - NCT05378204Recruiting
Testing DNA repair marker for PARP inhibitor resistance
This study looks at specific DNA “damage repair” proteins as a marker to understand why some BRCA-mutated breast cancers may resist PARP inhibitor treatment. Your biopsy (or existing biopsy) helps researchers study whether these lab markers relate to how well PARP inhibitors work.
BordeauxAges 18 years+ - NCT05400941Enrolling by invitation
Breast cancer follow-up support in primary care
This study looks at how breast cancer follow-up care can be better done in primary care clinics. It may help by improving care check-ins and support for people who have had breast cancer and for clinic staff involved in that care.
New Brunswick, New JerseyAges 21 years+ - NCT01840293Recruiting
Breast cancer study using tumor tissue to find key differences
This trial looks at breast cancer “proteins” and molecular features using tumor samples taken during surgery or biopsy. The goal is to better understand why breast cancers behave differently, which may help guide more personalized treatment in the future.
CorkAges 18 years+ - NCT05327608Recruiting
Time-restricted eating during chemo before breast cancer surgery
This study tests whether eating only during a certain window of time each day (time-restricted eating) can improve outcomes for people with early-stage breast cancer who are getting chemotherapy before surgery. It may help with treatment side effects and overall health.
Cherry Hill, New JerseyAges 18 years+ - NCT05301881RecruitingPhase 2
Continuing current treatment after local treatment for limited cancer growth
This trial tests whether continuing your current therapy after getting local treatment (like surgery or radiation) for a small area of cancer growth is safe and effective. It may help you keep the same treatment longer before switching to a new one.
AlkmaarAges 18 years+ - NCT04965766RecruitingPhase 2
Study drug for HER2-negative, advanced breast cancer after prior treatment
This Phase 2 trial tests patritumab deruxtecan (U3-1402) in people with HER2-negative, hormone-receptor positive (HR+) breast cancer that cannot be removed by surgery or has spread. It’s for cancers that have progressed despite endocrine therapy plus a CDK4/6 inhibitor, aiming to shrink tumors and control the disease.
DijonAges 18 years+ - NCT04636710Recruiting
Treatment approach study for stage III inflammatory breast cancer
This study looks at how to best plan local treatments (like surgery and/or radiation) for people with stage III inflammatory breast cancer. It may help doctors refine care plans for this aggressive subtype by studying how patients are treated and what outcomes they have.
Boston, MassachusettsAges 18 years+ - NCT05072314RecruitingPhase 3
Lidocaine drip after breast surgery to improve long-term pain
This Phase 3 study tests whether a long-running lidocaine (a numbing medicine) drip given around the time of breast surgery can improve long-term post-surgery pain and recovery. It may help people who have pain after mastectomy or breast-conserving surgery.
Kingswood, New South WalesAges 18 years+ - NCT05092373RecruitingPhase 1
Tumor treating device plus targeted or immune drugs for advanced cancers
This Phase 1 study tests whether a tumor treating fields device works better when added to standard cancer drugs. It may help people with advanced solid tumors in the chest or belly, especially when standard treatment didn’t work or can’t be tolerated.
Houston, TexasAges 18 years+ - NCT04916990Recruiting
Care program for rural adults with several lung and head cancers
This study looks at how to improve care for adults with certain cancers who live in rural areas and may face access problems. It mainly focuses on people receiving cancer treatment at specific Colorado-area hospitals, and who are uninsured or underinsured.
Aurora, ColoradoAges 18–99
Hear when a new Primary Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for primary breast cancer?
- Yes. Clin2 currently lists 711 recruiting primary breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a primary breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a primary breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.